Semax
Research draft Brain and mood research Best evidence grade B Human research reviewed, scope limited
Evidence design, not proof of benefit or product approval
Holds on this record
- No supplier batch has been matched to this record. A reviewer must record batch evidence before approval.
- Not marked ready for client selection in the library.
- No human administration guide. Study routes are research descriptions, not instructions.
- Research draft. Not released customer guidance.
The nine headings
Each heading opens a plain summary, then the deeper evidence and the sources behind it.
What it is A seven-link peptide. Check the product identity.
Semax is a synthetic chain of seven amino acids. Its sequence is Met–Glu–His–Phe–Pro–Gly–Pro. It was designed from part of ACTH, a hormone involved in the stress system. Semax is a modified fragment, not a dose of ACTH.
The identity of a molecule and the identity of your bottle are two separate checks. The standard Russian nasal product, a compounded spray and modified analogues cannot be treated as one tested product. This record names Semax; it has not verified a supplier batch.
Sources for this tile
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
Go deeper
The exact chain Open the checked detail
Seven links: methionine, glutamate, histidine, phenylalanine, proline, glycine and proline. The added end of the chain changes the parent fragment. This identity fact is not proof of a clinical benefit.
Sources
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
Which product was tested? Open the checked detail
Match the named molecule, salt form, concentration and delivery device to each source. This review does not substitute N-acetyl Semax, amidated Semax or a blend for the Semax used in the cited papers.
Sources
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
The history How the molecule and its research developed.
The manufacturer dates the start of Semax development to 1980, with teams at Moscow State University and the Institute of Molecular Genetics. It credits peptide work led by I. P. Ashmarin and synthesis under N. F. Myasoedov in 1985.
Its chronology gives 1994 as the first Russian registration of the 0.1% product. Later papers examined several neurological settings. This is a manufacturer’s history. Time on the market and a registration date do not settle whether it meets a particular person’s goal.
Sources for this tile
- Semax: manufacturer history (Manufacturer chronology, not a clinical study · checked 2026-10-09)
Go deeper
From development to clinical questions Open the checked detail
1980: development began. 1985: synthesis reported. 1994: first Russian registration reported. The timeline is sourced to the manufacturer and is kept separate from treatment evidence.
Sources
- Semax: manufacturer history (Manufacturer chronology, not a clinical study · checked 2026-10-09)
How it works Nerve-support pathways, with the model beside the claim.
One research idea concerns BDNF and NGF, proteins linked to nerve-cell support. In rats, Semax changed the activity of genes for these proteins. The changes depended on the brain region. In cell cultures, researchers also measured growth-factor gene changes.
That supports a pathway hypothesis, not a claim that Semax repairs your brain or raises every growth factor. Human imaging and blood markers belong in their own layer. They do not show a proven receptor mechanism or guarantee better thinking.
Sources for this tile
- Agapova et al., 2007: Semax and growth-factor genes in rats (Original study abstract; animal intervention · checked 2026-10-09)
- Shadrina et al., 2001: Semax in glial cell cultures (Original abstract; cell culture, not people · checked 2026-10-09)
Each proposed mechanism
Regional growth-factor gene activity
Animal findings vary by brain region.
Evidence note: C
Sources
- Agapova et al., 2007: Semax and growth-factor genes in rats (Original study abstract; animal intervention · checked 2026-10-09)
Glial culture growth-factor gene activity
Cell-culture work does not establish a human treatment effect.
Evidence note: D
Sources
- Shadrina et al., 2001: Semax in glial cell cultures (Original abstract; cell culture, not people · checked 2026-10-09)
Go deeper
Nerve-support signals C C · Claim-specific evidence
C · Rats. Agapova and colleagues gave intranasal Semax and measured growth-factor genes one hour later. The response varied by brain region; one NGF signal decreased in the frontal cortex. A universal “brain-growth boost” would misstate this experiment.
Sources
- Agapova et al., 2007: Semax and growth-factor genes in rats (Original study abstract; animal intervention · checked 2026-10-09)
Cells in a dish D D · Claim-specific evidence
D · Shadrina and colleagues studied glial cultures from newborn rats. BDNF and NGF gene activity changed after exposure. These were cultured cells, not adults taking a spray.
Sources
- Shadrina et al., 2001: Semax in glial cell cultures (Original abstract; cell culture, not people · checked 2026-10-09)
The human marker bridge B B · Claim-specific evidence
B · A stroke-rehabilitation comparison measured blood BDNF alongside daily-function scores. A blood marker can support a research question. It does not prove that a healthy person has low BDNF or needs this peptide.
Sources
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
What it helps Separate stroke-recovery research from healthy-person claims.
Stroke rehabilitation is a human research topic for Semax. A clinical comparison reported changes in daily-function scores and blood BDNF. The participants were recovering from ischemic stroke, where blocked blood flow had injured the brain.
Healthy-adult MRI work asked a different question: whether brain-network patterns change after administration. It did not establish better work performance, memory or focus. The library keeps those two questions apart and does not turn a stroke result into a broad promise for a healthy client.
Sources for this tile
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
Read this before you read a benefit into it
Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.
Human research found for this product
Semax: stroke rehabilitation comparison B
| Proof grade | B |
|---|---|
| Design | Clinical comparison; randomization and blinding not established from the checked abstract |
| People or model | Early or late rehabilitation after ischemic stroke |
| Number | 110 |
| Outcome measured | Blood BDNF, movement and Barthel daily-function score |
| Result | Authors report higher BDNF and faster daily-function recovery with Semax. A usable between-group effect size is absent from the abstract. Rehabilitation timing also mattered. |
| Route in the study | Not explicit in the abstract; do not infer an injection route |
| Duration | Two 10-day courses with a 20-day gap |
| Risks noted | Adverse-event details not supplied in the checked abstract |
| Regimen seen in the study | 6 mg/day (6000 mcg/day); stroke-study reference only |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
Lebedeva et al., 2018: Semax and resting brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; randomization and blinding not confirmed in the abstract |
| People or model | Healthy adults: 14 received Semax, 10 placebo |
| Number | 24 |
| Outcome measured | Resting-state MRI network activity |
| Result | A frontal part of a brain network differed after Semax. No measured improvement in daily focus, memory or work was established by this imaging endpoint. |
| Route in the study | Intranasal 1% formulation |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; allocation and blinding details not established in the abstract |
| People or model | Healthy participants in separate Semax, Selank or placebo arms |
| Number | 52 |
| Outcome measured | Resting-state MRI connectivity |
| Result | The authors report changes in links between the right amygdala and right temporal regions. This does not establish a benefit from taking both peptides together. |
| Route in the study | Abstract uses the word injection without a usable route description; full-text route check remains open |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Animal and laboratory records
Agapova et al., 2007: Semax and growth-factor genes in rats C
| Proof grade | C |
|---|---|
| Result | Regional growth-factor gene changes; abstract did not state sample size |
| Duration | Gene-expression measurement one hour later |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Agapova et al., 2007: Semax and growth-factor genes in rats (Original study abstract; animal intervention · checked 2026-10-09)
Go deeper
Function after stroke B B · Claim-specific evidence
B · The relevant outcome was recovery of daily function during rehabilitation. This is a restricted patient group. The abstract alone does not settle treatment effectiveness or replace a complete clinical review.
Sources
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
Brain networks in healthy adults A A · Claim-specific evidence
A · Small controlled imaging study. An MRI network change is a measured brain signal, not a demonstrated improvement in the person’s life.
Sources
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
What is not established here Open the checked detail
Healthy-person productivity, memory gains and long-term brain protection have not been established by the checked outcomes. Do not sell these as cleared benefits from this record.
Sources
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
The research Proof grades, current review and open questions.
The reviewed evidence reaches people, animals and cultured cells. Each result keeps its own grade, tested group and outcome. The deeper layer names the sources, study sizes, observed regimens, missing details and questions still open.
The FDA’s May 2026 evaluation found insufficient evidence for the nominated stroke-related, migraine and facial-nerve pain uses, and insufficient clinical safety information. It is an advisory evaluation, not a final drug-approval decision. Published positive findings still need to be weighed against study limits.
Sources for this tile
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Overall state of the evidence
Status: scoped-human-evidence
Claim-specific evidence. No personal suitability or regimen approval. See individual study limitations.
Risk summary
The 0.1% product instruction excludes anxiety disorders, acute psychiatric states, a seizure history, pregnancy, breastfeeding and sensitivity to its ingredients. It notes nasal irritation and advises against local nasal vasoconstrictors. These belong beside a proposed plan, not behind a generic footnote.
An individual stop plan is not recorded here. The medicine list, formulation and each personal reason to stop still need review.
What is still open
- Exact supplier, formulation, pump delivery and batch match unverified
- Personal health record and suitability not assessed
- Human half-life and complete interaction review not established
- Scoped reviewed sources, not an exhaustive literature review
Checks a reviewer must finish first
- Exact formulation
- Neurological history and medicines
- Baseline function and evidence for the intended goal
How to read the proof grades
- A: Controlled human trial. Note whether randomisation and blinding were confirmed.
- B: Small uncontrolled human study or chart review.
- C: Whole-animal intervention.
- D: Cell or other laboratory study.
- E: User reports. Kept separate and never substituted for a measured outcome.
- ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.
Go deeper
How to read the proof Open the checked detail
A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.
A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Current evidence review Open the checked detail
FDA evaluation dated 11 May 2026: effectiveness evidence and clinical safety data were insufficient for the uses reviewed. Human pharmacokinetic data were not identified. This does not support an exact human half-life or a claim that compounded products are proven safe.
Sources
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
Animal and cell records Open the checked detail
C: regional growth-factor gene changes in rats. D: growth-factor gene changes in rat glial cultures. Neither is a clinical outcome. Open How it works for the individual source and model.
Sources
- Agapova et al., 2007: Semax and growth-factor genes in rats (Original study abstract; animal intervention · checked 2026-10-09)
- Shadrina et al., 2001: Semax in glial cell cultures (Original abstract; cell culture, not people · checked 2026-10-09)
Researcher layer Open the checked detail
Sequence and origin are recorded under identity. Reviewed human studies appear in Research in people. Human half-life, full clearance data and a full medicine-interaction review remain open.
No personal dose, cycle or stop plan is filled in. This is a scoped review of named sources, not an exhaustive review of every Semax paper. Supplier and batch match remain unverified.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
- FDA Semax evaluation, 11 May 2026 (Evidence and safety conclusions read; advisory evaluation, not a final approval decision · checked 2026-10-09)
Research in people People, design, result, amount and limits.
The checked human records include a 110-person stroke-rehabilitation comparison, a 24-person placebo comparison using brain scans, and a 52-person scan study with separate Semax, Selank and placebo arms. These trials asked different questions.
Open each study to see who took part, what was measured, the design limits and the regimen where it is known. The 52-person paper does not test taking Semax and Selank together. No personal treatment plan is approved by placing a human paper in this library.
Sources for this tile
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
What people report
No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.
Each human record
Semax: stroke rehabilitation comparison B
| Proof grade | B |
|---|---|
| Design | Clinical comparison; randomization and blinding not established from the checked abstract |
| People or model | Early or late rehabilitation after ischemic stroke |
| Number | 110 |
| Outcome measured | Blood BDNF, movement and Barthel daily-function score |
| Result | Authors report higher BDNF and faster daily-function recovery with Semax. A usable between-group effect size is absent from the abstract. Rehabilitation timing also mattered. |
| Route in the study | Not explicit in the abstract; do not infer an injection route |
| Duration | Two 10-day courses with a 20-day gap |
| Risks noted | Adverse-event details not supplied in the checked abstract |
| Regimen seen in the study | 6 mg/day (6000 mcg/day); stroke-study reference only |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
Lebedeva et al., 2018: Semax and resting brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; randomization and blinding not confirmed in the abstract |
| People or model | Healthy adults: 14 received Semax, 10 placebo |
| Number | 24 |
| Outcome measured | Resting-state MRI network activity |
| Result | A frontal part of a brain network differed after Semax. No measured improvement in daily focus, memory or work was established by this imaging endpoint. |
| Route in the study | Intranasal 1% formulation |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A
| Proof grade | A |
|---|---|
| Design | Small placebo comparison; allocation and blinding details not established in the abstract |
| People or model | Healthy participants in separate Semax, Selank or placebo arms |
| Number | 52 |
| Outcome measured | Resting-state MRI connectivity |
| Result | The authors report changes in links between the right amygdala and right temporal regions. This does not establish a benefit from taking both peptides together. |
| Route in the study | Abstract uses the word injection without a usable route description; full-text route check remains open |
| Duration | Scans before, then 5 and 20 minutes after administration |
| Risks noted | Not detailed in the checked abstract |
| Personal regimen | Not set. A study regimen is not a personal instruction. |
Source
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Go deeper
Semax: stroke rehabilitation comparison B B · Claim-specific evidence
People: Early or late rehabilitation after ischemic stroke. Total: 110. Design: Clinical comparison; randomization and blinding not established from the checked abstract.
Measured: Blood BDNF, movement and Barthel daily-function score. Authors report higher BDNF and faster daily-function recovery with Semax. A usable between-group effect size is absent from the abstract. Rehabilitation timing also mattered.
Route: Not explicit in the abstract; do not infer an injection route. Duration: Two 10-day courses with a 20-day gap. 6 mg/day (6000 mcg/day); stroke-study reference only
Safety: Adverse-event details not supplied in the checked abstract. Personal regimen: not approved.
Sources
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
Lebedeva et al., 2018: Semax and resting brain networks A A · Claim-specific evidence
People: Healthy adults: 14 received Semax, 10 placebo. Total: 24. Design: Small placebo comparison; randomization and blinding not confirmed in the abstract.
Measured: Resting-state MRI network activity. A frontal part of a brain network differed after Semax. No measured improvement in daily focus, memory or work was established by this imaging endpoint.
Route: Intranasal 1% formulation. Duration: Scans before, then 5 and 20 minutes after administration. Dose not established in this review.
Safety: Not detailed in the checked abstract. Personal regimen: not approved.
Sources
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
Panikratova et al., 2020: Selank, Semax and brain networks A A · Claim-specific evidence
People: Healthy participants in separate Semax, Selank or placebo arms. Total: 52. Design: Small placebo comparison; allocation and blinding details not established in the abstract.
Measured: Resting-state MRI connectivity. The authors report changes in links between the right amygdala and right temporal regions. This does not establish a benefit from taking both peptides together.
Route: Abstract uses the word injection without a usable route description; full-text route check remains open. Duration: Scans before, then 5 and 20 minutes after administration. Dose not established in this review.
Safety: Not detailed in the checked abstract. Personal regimen: not approved.
Sources
- Panikratova et al., 2020: Selank, Semax and brain networks (Original abstract; separate treatment arms, not a combined stack · checked 2026-10-09)
Why it is for you Built from your own profile, once reviewed.
This tile begins with the person’s own words. It then links each concern to a named research question, the matching proof and the reasons to rule an option out. A goal such as better focus does not prove a damaged pathway.
No personal assessment or approved plan is recorded here. The shared library therefore does not call this peptide right for you. Your symptoms, medicines, history, baseline and stop wishes must be held in your own profile, outside this shared record.
Sources for this tile
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
Go deeper
Your words and top three concerns Open the checked detail
Not filled in. The personal profile will preserve the original answers. Any interpretation must stay separate from what the person actually said.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
The target and matching evidence Open the checked detail
Not filled in. A proposed biological target needs support. The profile must name the relevant study population, outcome and limits before suggesting this option.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Phase, baseline and stop wishes Open the checked detail
Not agreed. Record one change at a time, the starting measure, a check date and the person’s own stop wishes. Do not infer doses or cycles from a catalog entry.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
What you would notice A measured check-in, not a promised feeling.
The checked research cannot promise that you will feel sharper, calmer or more energetic. A brain-scan change may not be felt at all. A result in stroke rehabilitation also does not say what a healthy person will notice.
The personal layer should pick one goal, record a starting measure and set a check date before any approved change. Use the same measure at follow-up. Record anything new or unwelcome too. The published 0.1% instruction notes nasal irritation with prolonged use; other risk questions stay open.
Sources for this tile
- Lebedeva et al., 2018: Semax and resting brain networks (Original study abstract; 24 healthy adults, imaging outcome · checked 2026-10-09)
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
Go deeper
Choose a measure before a change Open the checked detail
Example of a tracking field, not an efficacy claim: ability to complete the same daily task, sleep log or a stated symptom rating. Select the measure from the person’s goal. Leave the target and check date blank until agreed.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Rule-outs and stop signs Open the checked detail
The 0.1% product instruction excludes anxiety disorders, acute psychiatric states, a seizure history, pregnancy, breastfeeding and sensitivity to its ingredients. It notes nasal irritation and advises against local nasal vasoconstrictors. These belong beside a proposed plan, not behind a generic footnote.
An individual stop plan is not recorded here. The medicine list, formulation and each personal reason to stop still need review.
Sources
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
How it is taken Nasal references, spray arithmetic and the personal plan.
The checked product reference is nasal. For mental-fatigue prevention, the manufacturer’s 0.1% instruction corresponds to 0.2–0.3 mg per administration, two or three times in the first half of the day, over three to five days. That is a product-specific reference, not an approved schedule for your bottle.
Open the spray card for your stated 0.1 mg per pump. It shows the amount per administration and the daily total. Product strength, device instructions, storage and the agreed personal plan remain distinct fields. No injection or mixing recipe is inferred from these nasal sources.
Sources for this tile
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
Routes seen in the research
- Nasal product references; study-specific route recorded separately
Dose and cycle fields in the library
These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.
| dose | Blank |
|---|---|
| unit | Blank |
| frequency | Blank |
| timeOfDay | Blank |
| foodTiming | Blank |
| route | Blank |
| injectionSite | Blank |
| cycleLength | Blank |
| restLength | Blank |
| titration | Blank |
| mixing | Blank |
| storage | Blank |
| expiryAfterMixing | Blank |
Go deeper
Your measured spray: milligrams and micrograms Open the checked detail
Calculation example using the stated 0.1 mg per full spray. That equals 100 micrograms (mcg). This amount per pump has not been checked against a bottle label.
At that stated strength: 3 sprays TOTAL = 0.3 mg = 300 mcg per administration. Two such administrations = 0.6 mg/day = 600 mcg/day. Three = 0.9 mg/day = 900 mcg/day. Three sprays in EACH nostril means 6 sprays total and doubles those amounts.
These are unit calculations. They do not set a personal schedule. Mass per spray is not the same as liquid volume per spray.
Published timing and course Open the checked detail
Reference: 0.2–0.3 mg per administration. Two or three administrations in the first half of the day. Course: 3–5 days for the label’s mental-fatigue indication. Exact clock times are not specified. This short reference is not a monthly or lifelong cycle.
Sources
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
The agreed personal administration card Open the checked detail
Approval status: no personal regimen approved in this record. Exact bottle, strength per pump, total sprays per administration, administrations per day, daily total, dates, review and stop signs are blank.
A published regimen stays in the reference layer. The app must not turn it into a personal instruction merely because its arithmetic matches a spray bottle.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Storage and device Open the checked detail
For the cited manufactured product: protect from light, keep at or below 10°C and do not freeze. This instruction does not establish the opened-bottle life of a compounded spray. Follow the exact bottle’s dispenser, priming, storage and expiry information; those have not been checked here.
Sources
- Semax 0.1%: manufacturer instruction (Three-page product instruction; formulation, reference schedule and exclusions · checked 2026-10-09)
Stroke-study regimen stays in the study B B · Claim-specific evidence
The 2018 rehabilitation paper reports 6 mg/day in two 10-day courses with a 20-day gap. That amount belongs to the reported stroke study. It is not a general focus regimen and is not copied into the personal spray card.
Sources
- Semax: stroke rehabilitation comparison (Gusev and colleagues · 2018 · Published abstract · checked 2026-10-09)
Identity
| What it is made of | Semax is a synthetic chain of seven amino acids. Its sequence is Met–Glu–His–Phe–Pro–Gly–Pro. It was designed from part of ACTH, a hormone involved in the stress system. Semax is a modified fragment, not a dose of ACTH. |
|---|---|
| Chain | Met-Glu-His-Phe-Pro-Gly-Pro |
| Chain length | 7 |
| Origin | Synthetic modified ACTH-fragment peptide |
| Maker | Not recorded |
| Supplier batch matched | No. Not matched to a supplier batch. |
| Catalog sizes | 5mg to 10mg - Inherited reference only; stock and current product sizes unverified |
| Record checked on | 2026-10-09 |
Shared safety note
FDA flags immune reactions and impurities in several compounded peptides. Its notice also reports serious events in IV ipamorelin research, heart-rate and vessel-dilation reactions with CJC-1295, glucose concerns with GHRP-2/6, and serious case reports with melanotan II. Reports do not by themselves establish causation. This concerns proposed compounded products and routes, not every formulation worldwide.
Source
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)